AnorMED

AnorMED, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic drugs aimed at treating hematological disorders, human immunodeficiency virus (HIV), and cancer. The company's lead drug product candidate, MOZOBIL, is currently in phase III clinical trials and is designed for cancer patients undergoing stem cell transplantation. Additionally, AnorMED is developing AMD070, an HIV entry inhibitor that is in phase Ib/IIa trials. Through its innovative therapeutic approaches, AnorMED seeks to address significant medical needs in these critical areas of healthcare.